Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Fifth Annual Rare Disease Day Highlights the Need for More Research

Published: Wednesday, February 29, 2012
Last Updated: Wednesday, February 29, 2012
Bookmark and Share
New Genefficiency™ Targeted Sequencing Service from OGT, designed to support the genetic analysis of rare diseases.

Today is the 5th annual Rare Disease Day, designed to raise global awareness amongst the general public and policy makers about rare diseases and their impact on patient’s lives. Information recently released by EURORDIS, the organiser of Rare Disease Day 2012, suggests that “due to the low prevalence of each disease, medical experts are rare, knowledge is scarce, care offering inadequate, and research limited.” To meet the need for further research into this area, Oxford Gene Technology (OGT), a provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has recently announced a dedicated rare disease version of its Genefficiency™ Targeted Sequencing Service, as many rare diseases have a genetic basis that is best studied using high resolution molecular tools. By utilising the service, it is now faster and easier than ever before for researchers and clinicians to investigate the biological nature of a given disease, so that more effective treatment strategies can be designed and implemented.

OGT’s Chief Executive Officer, Dr Mike Evans, commented: “The Rare Disease Day campaign plays a significant role in raising the awareness of debilitating and life-threatening diseases. Although in combination these diseases affect millions worldwide, their individual rarity combined with the relative complexity of carrying out in-depth genomic analysis has meant that these diseases have not traditionally attracted extensive research efforts. To help promote research in this area, our Genefficiency Targeted Sequencing Service includes an optimised offering for investigating rare diseases. Clinicians and researchers can now assess the genetic basis of any disease, without the need for expensive in-house hardware, or internal technical and bioinformatics expertise. By making such research easier to carry out, we hope to help improve the quality of life for rare disease patients.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Initiates Clinical Trial of New Array-Based NIPT
Proprietary microarray technology will be fast, cost-effective, and will enable clinical laboratories to offer NIPT in-house.
Tuesday, November 04, 2014
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Supports Earlier Lupus Diagnosis
Superior sensitivity and specificity compared to current laboratory tests.
Friday, May 10, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT to Host Company Showcase at BioTrinity 2012
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.
Monday, April 23, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
OGT to Exhibit and Present at Molecular Medicine Tri-Con 2012
The conference will include an OGT presentation entitled “Integrated Biomarker Discovery: Multi-Method Approach to Enable Early Biomarker Success”, taking place on Tuesday 21st February at 15.50 in the Moscone North Convention Centre.
Friday, February 10, 2012
OGT Founder Professor Sir Ed Southern Awarded the 2011 MRC Millennium Medal
Pioneer of DNA microarray technology recognised for outstanding impact in the field of genetic analysis.
Monday, January 30, 2012
OGT Releases New Whitepaper for Aiding Biomarker Discovery
The new document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.
Tuesday, January 24, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT Featured in the Sunday Times Biotech Supplement
The article entitled ‘Better diagnosis, less cost’, describes how OGT’s recent innovations will help push healthcare costs down, while improving the accuracy of early disease diagnosis.
Monday, January 24, 2011
OGT Announces Major Role in Large Scale Diabetes Study
Genefficiency™ aCGH microarray service to process extensive sample set linking CNVs to disease susceptibility.
Thursday, December 02, 2010
OGT Receives ISO/IEC 27001:2005 Accreditation
Certification highlights commitment to information security and confidentiality.
Thursday, September 16, 2010
OGT Attracts Over 200 Delegates to its aCGH Satellite Meeting at ESHG 2010
Delegates heard presentations on how OGT’s array comparative genomic hybridization solutions can help advance disease and cytogenetics research.
Tuesday, July 13, 2010
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos